{"id":"NCT02916706","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09","primaryCompletion":"2018-08-14","completion":null,"firstPosted":"2016-09-27","resultsPosted":"2022-01-28","lastUpdate":"2022-03-09"},"enrollment":254,"design":{"allocation":null,"model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Teneligliptin 20mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Teneligliptin 20mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin).","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 24","timeFrame":"at Day 1(baseline) and Week 24","effectByArm":[{"arm":"Teneligliptin 20mg","deltaMin":-0.95,"sd":0.06},{"arm":"Placebo","deltaMin":-0.14,"sd":0.06}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":3},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":127},"commonTop":["Upper respiratory tract infection","Hyperuricaemia","Hypoglycaemia","Hyperlipidaemia","Proteinuria"]}}